Eureka Report - How Anteris Technologies got its credibility back

CEO Wayne Paterson (Anteris Technologies) is interviewed by Alan Kohler, Editor-in-Chief at Eureka Report

Q&A with StockPal - Anteris Technologies (ASX:AVR)

CEO W. Paterson interviewed by J. Sim, Editor-in-Chief & Co-Founder at StockPal.

Bioshares - Anteris Demonstrates ADAPT Process Outperforms Medtronic's AOA Process in Animal Study

Bioshares - Anteris Demonstrates ADAPT Process Outperforms Medtronic's AOA Process in Animal Study

Anteris Technologies (ASX:AVR) interview with Proactive Investors

Anteris Technologies Ltd's (ASX:AVR) (OTCMKTS:AMEUF) (FRA:DDF) Wayne Paterson tells Proactive's Andrew Scott its share price has moved up to reflect the progress of the last two years.

ASX Small Mid Conference - Anteris Technologies

Anteris Technologies ASX SMID Conference on demand video

FNN Online Investor Event

Anteris Technologies (ASX:AVR) Presentation FNN Online Investor Event

Notice of Extraordinary General Meeting

To be held 19th March 2021

MST Access - Q4 Results: Fresh Funds Available

Trials progressing well

CEO Wayne Paterson is interviewed by 180 Markets

CEO Wayne Paterson interview with 180 Markets

Anteris Technologies (ASX:AVR) nabs $20M funding package

CEO W. Paterson discusses the new funding package and upcoming FDA activities

Anteris set the stage in 2020 to prepare for DurAVR™ THV to be implanted in humans in 2021

""

DurAVR™ selected as Best Innovation in Aortic Valve Therapy at PCR Valves eCourse 2020

DurAVR™ FIH was selected from PCRValves eCourse 2020 as Best Innovation.